These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 18376220)
1. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. Cohen SJ; Engstrom PF; Lewis NL; Langer CJ; McLaughlin S; Beard M; Weiner LM; Meropol NJ Am J Clin Oncol; 2008 Feb; 31(1):1-5. PubMed ID: 18376220 [TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity. Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674 [TBL] [Abstract][Full Text] [Related]
3. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer. Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751 [TBL] [Abstract][Full Text] [Related]
4. A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors. Amarantidis K; Xenidis N; Chelis L; Chiotis A; Tentes A; Chatzaki E; Kortsaris A; Polychronidis A; Karakitsos P; Kakolyris S Acta Oncol; 2010; 49(2):245-51. PubMed ID: 19839918 [TBL] [Abstract][Full Text] [Related]
5. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990 [TBL] [Abstract][Full Text] [Related]
6. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Samonis G; Vardakis N; Amarantidis K; Agelaki S; Mavroudis D; Xenidis N; Georgoulias V Oncology; 2004; 66(4):253-9. PubMed ID: 15218291 [TBL] [Abstract][Full Text] [Related]
7. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma. Fakih MG; Rajput A; Yang GY; Pendyala L; Toth K; Smith JL; Lawrence DD; Rustum YM Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1462-70. PubMed ID: 16750332 [TBL] [Abstract][Full Text] [Related]
8. A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. Evans D; Miner T; Akerman P; Millis R; Jean M; Kennedy T; Safran H Am J Clin Oncol; 2007 Aug; 30(4):346-9. PubMed ID: 17762433 [TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330 [TBL] [Abstract][Full Text] [Related]
10. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108. Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer. Xiang XJ; Zhang L; Qiu F; Yu F; Zhan ZY; Feng M; Yan J; Zhao JG; Xiong JP Chemotherapy; 2012; 58(1):1-7. PubMed ID: 22310723 [TBL] [Abstract][Full Text] [Related]
12. A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors. Dennie TW; Fleming RA; Bowen CJ; Dar MM; Alberti D; Oliver K; Loconte N; Mulkerin D; Holen KD Clin Colorectal Cancer; 2011 Mar; 10(1):57-62. PubMed ID: 21609937 [TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Shields AF; Zalupski MM; Marshall JL; Meropol NJ Cancer; 2004 Feb; 100(3):531-7. PubMed ID: 14745869 [TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer--an extended phase I MARGIT and AIO trial. Hofheinz RD; Wenz F; Lukan N; Mai S; Kripp M; Staiger W; Schwarzbach M; Willeke F; Möhler M; Post S; Hochhaus A Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):142-7. PubMed ID: 18539404 [TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Dreicer R; Petrylak D; Agus D; Webb I; Roth B Clin Cancer Res; 2007 Feb; 13(4):1208-15. PubMed ID: 17317831 [TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Hainsworth JD; Spigel DR; Burris HA; Shipley D; Farley C; Macias-Perez IM; Barton J; Greco FA Cancer; 2010 May; 116(10):2448-54. PubMed ID: 20209610 [TBL] [Abstract][Full Text] [Related]
17. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Rödel C; Arnold D; Hipp M; Liersch T; Dellas K; Iesalnieks I; Hermann RM; Lordick F; Hinke A; Hohenberger W; Sauer R Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1081-6. PubMed ID: 17881150 [TBL] [Abstract][Full Text] [Related]
18. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer. Amarantidis K; Xenidis N; Chelis L; Chamalidou E; Dimopoulos P; Michailidis P; Tentes A; Deftereos S; Karanikas M; Karayiannakis A; Kakolyris S Oncology; 2011; 80(5-6):359-65. PubMed ID: 21811088 [TBL] [Abstract][Full Text] [Related]
19. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. Caponigro F; Lacombe D; Twelves C; Bauer J; Govaerts AS; Marréaud S; Milano A; Anthoney A Eur J Cancer; 2009 Jan; 45(1):48-55. PubMed ID: 18809314 [TBL] [Abstract][Full Text] [Related]
20. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]